ExploreWatchlistsPricing
  1. JP-listed companies
  2. WAKAMOTO PHARMACEUTICAL CO.,LTD.
  3. Financials
  4. Cash from operations

WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512)

Market cap
¥11.8B
P/E ratio
51.4x
Wakamoto Pharmaceutical manufactures branded drugs, generic medicines, and health products like Koryoku Wakamoto for healthcare providers and consumers in Japan and internationally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Mar 31, 2026-487-17.81%
Mar 31, 2025-592+451.95%
Mar 31, 2024-107-116.99%
Mar 31, 2023632+86.31%
Mar 31, 2022339+107.52%
Mar 31, 2021163-205.40%
Mar 31, 2020-155+35.44%
Mar 31, 2019-114-120.60%
Mar 31, 2018556-49.40%
Mar 31, 20171,098+84.80%
Mar 31, 2016594-49.43%
Mar 31, 20151,175

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat